Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT03421119
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Cinnagen
- Registry
-
NCT03421119
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03421119. Randomized; triple masking; primary purpose treatment. Start 2019-06-20 (anticipated); primary completion 2019-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Liraglutide 6 MG/ML Pen Injector
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulfonylurea/non-sulfonylurea insulin secretagogues
- Lead sponsor
- Cinnagen
Record details
- Record id
cardio:ct-nct03421119- Content hash
0647b56b64241f653558a314051e21250a0fb80926c9064a2e91dc6c1957d131